Epidermal growth factor receptor (EGFR) is a validated target in different human
malignancies. EGFR tyrosine kinase inhibitors (TKIs) are known to contribute considerably …

Abstract The Epidermal Growth Factor Receptor (EGFR) has been targeted through the
development of selective tyrosine kinase inhibitors (TKIs) and monoclonal antibodies (mAb) …

In recent years, the epidermal growth factor receptor (EGFR) has been recognized as a
central player and regulator of cancer cell proliferation, apoptosis and angiogenesis and …

EGFR is a validated therapeutic target in many human cancers. EGFR targeted therapies
are in widespread clinical use in patients with non-small cell lung cancer and other tumor …

Epidermal growth factor receptor (EGFR) plays a key role in tumour evolution, proliferation
and immune evasion, and is one of the most important targets for biological therapy …

EGFR is a tyrosine kinase that participates in the regulation of cellular homeostasis.
Following ligand binding, EGFR stimulates downstream cell signaling cascades that …

Since the recognition of epidermal growth factor receptor (EGFR) as a therapeutic target,
EGFR tyrosine kinase inhibitors (TKIs) have been used in lung cancer patients with EGFR …

Epidermal growth factor receptor (EGFR) inhibitors were among the first type of targeted
agents discovered in cancer and currently constitute the standard of care for a wide range of …

The clinical introduction of EGFR-TKIs within the oncologic armamentarium has changed the
therapeutic landscape of non-small-cell lung cancer (NSCLC) creating widespread …

Aberrant expression of the epidermal growth factor receptor (EGFR) system has been
reported in a wide range of epithelial cancers. In some studies, this has also been …